

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Assistant Commissioner for Patents
Washington, D.C. 20231

1614
PATENT
Attorney Docket No.: 15270J-004750US
Client Reference No.: 00209-US-CIP

On October 30, 2000

TOWNSEND and TOWNSEND and CREW LLP

By: Ch. Fitting



#5
RECEIVED
NOV 07 2000
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale Schenk et al.

Application No.: 09/580,015

Filed: May 26, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Unassigned

Art Unit: 1614

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 09/201,430, filed 11/30/98 (Attorney Docket No. 15270J-004720US). Submitted herewith is a copy of the application submitted by Victor Raso for NIH Grant No. IR43AG15746-01 on August 29, 1997. Applicants also cite commonly owned copending applications directed to related subject matter:

09/201,430, filed 11/30/98;
09/322,289, filed 05/28/99;
09/497,553, filed 02/03/00
09/580,018, filed 05/26/00;


09/580,019, filed 05/26/00;
09/585,817, filed 06/01/00.

Applicants also cite 09/204,838, filed 12/3/98, which is now commonly assigned but was previously subject to different assignment than the present application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JOL:crf